CoverageForm 410-K10-Q8-K13D13G13F

SNYR · Synergy Chc Corp. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · SNYR

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q4 '23Q1 '20Q4 '19
Revenue$5.49M-$8.01M$8.13M$30.00M-$10.81M-$6.12M-
Cost of Revenue$1.52M-$2.33M$2.45M$2.64M-$3.03M-$1.50M-
Gross Profit$3.97M-$5.68M$6.24M$6.77M-$7.78M-$4.62M-
R&D----------
SG&A$2.05M-$1.64M$1.52M$1.35M-$1.33M-$1.33M-
Total Operating Expenses$4.54M-$4.40M$3.99M$4.97M-$3.74M-$3.61M-
D&A$33.3K-$33.3K$33.3K$33.3K-$33.3K-$26.8K-
Operating Income($567.1K)-$1.28M$1.62M$1.81M-$2.15M-$1.01M-
Interest Expense$2.01M-$1.16M$745.5K$414.2K$40.0K$446.6K---
Income Tax($13.7K)-($11.1K)$179.4K$127.2K-($192.3K)-$285.5K-
Net Income($2.57M)-$125.3K$1.47M$876.3K-$1.28M-$262.3K-
EPS - Basic($0.23)-$0.01$0.09$0.08-$0.17-$0.00-
EPS - Diluted($0.23)-$0.01$0.09$0.08-$0.17-$0.00-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q4 '23Q1 '20Q4 '19
Cash & Equivalents$292.1K$2.62M$1.01M$1.46M$177.9K$687.9K$632.5K-$314.9K$1.22M
Accounts Receivable$1.27M$3.20M$6.81M$7.07M$4.38M$5.32M$4.07M-$3.04M$1.42M
Inventory$3.38M$3.74M$2.15M$2.36M$2.35M$1.72M$1.91M-$1.71M$1.86M
Accounts Payable----------
Current Assets$6.34M$10.01M$20.51M$19.51M$15.41M$16.06M$11.82M-$5.36M$5.05M
Total Assets$6.46M$10.16M$20.69M$19.73M$15.66M$16.34M$12.24M-$5.48M$5.19M
Current Liabilities$6.85M$8.24M$3.83M$7.13M$8.07M$17.18M$14.02M-$9.80M$10.15M
Long-term Debt$25.02M$25.06M$25.11M$24.98M$10.90M$7.46M-$13.10M--
Total Liabilities$31.87M$33.29M$28.94M$32.11M$31.30M$32.97M$37.34M-$10.05M$10.39M
Stockholders' Equity($25.41M)($23.13M)($8.25M)($12.38M)($15.64M)($16.63M)($27.31M)-($4.57M)($5.20M)
Retained Earnings($59.01M)($56.44M)($41.62M)($41.75M)($43.22M)($44.10M)($46.35M)-($23.97M)($24.23M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q4 '23Q1 '20Q4 '19
Operating Cash Flow($2.04M)---($858.0K)---($1.30M)-
Investing Cash Flow----------
Financing Cash Flow($307.6K)---$1.00M---$58.0K-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q4 '23Q1 '20Q4 '19
Profitability
Gross margin72.3%-70.9%76.7%22.6%-72.0%-75.5%-
Operating margin-10.3%-16.0%20.0%6.0%-19.9%-16.4%-
EBITDA margin-9.7%-16.4%20.4%6.1%-20.2%-16.9%-
Net margin-46.8%-1.6%18.1%2.9%-11.9%-4.3%-
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue37.3%-20.4%18.7%4.5%-12.3%-21.8%-
Effective tax rate---9.7%10.9%12.7%--17.6%-52.1%-
Return on assets-39.8%-0.6%7.5%5.6%-10.5%-4.8%-
Return on equity10.1%--1.5%-11.9%-5.6%--4.7%--5.7%-
Return on invested capital--7.6%11.5%------
Liquidity
Current ratio0.931.225.352.741.910.930.84-0.550.50
Quick ratio0.430.764.792.411.620.830.71-0.370.31
Cash ratio0.040.320.260.200.020.040.05-0.030.12
Leverage
Debt / Equity-0.98-1.08-3.04-2.02-0.70-0.45----
Debt / Assets3.872.471.211.270.700.46----
Debt / EBITDA--19.1215.075.92-----
Interest coverage-0.3x-1.1x2.2x4.4x-4.8x---
Equity multiplier-0.25-0.44-2.51-1.59-1.00-0.98-0.45--1.20-1.00
Liabilities / Assets4.933.281.401.632.002.023.05-1.832.00
Efficiency
Asset turnover0.85-0.390.411.92-0.88-1.12-
Inventory turnover0.45-1.091.041.12-1.58-0.87-
Days sales outstanding84d-310d317d53d-138d-181d-
Days inventory outstanding811d-336d352d325d-230d-418d-
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E--244.0x31.7x29.4x-----
P / B----------
P / S2.7x-3.1x2.6x0.6x-----
EV / EBITDA--37.1x26.9x15.2x-----
Growth
Revenue growth (YoY)-81.7%--25.9%------35.4%-
Revenue CAGR (3y)---------17.2%-
Revenue CAGR (5y)----37.4%-8.0%-30.8%-
Gross profit growth (YoY)-41.4%--27.0%------33.3%-
Operating income growth (YoY)---40.4%------44.9%-
Net income growth (YoY)---90.2%------82.1%-
EPS growth (YoY)---94.1%-------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-62.4%-39.1%69.8%-------

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$30.38M total
Nutraceuticals$29.73M · 97.9%
Beverages$631.3K · 2.1%
Consumer Goods$18.0K · 0.1%

Product / service

$33.28M total
Retail$22.25M · 66.9%
Online$8.13M · 24.4%
License Revenue$2.90M · 8.7%

Geographic

$30.38M total
US$27.32M · 89.9%
CA$2.42M · 8.0%
MX$623.7K · 2.1%
Other$20.7K · 0.1%

Peer comparison

Same SIC group: Medicinal Chemicals & Botanical Products

CompanyRevenue (last FY)Net marginROE
USNA$925.26M1.2%2.0%
TRUL$1.18B-9.9%-10.2%
CRON$146.59M-6.4%-0.9%
CYAN$24.21M-13.2%-36.1%
MNMD---55.3%

Comparing Synergy CHC Corp. against the 5 most active filers in the same SIC group.